バイオ後続品の世界市場分析

【英語タイトル】Biosimilars Market Analysis By Product (Recombinant Non-Glycosylated Proteins - Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormone, Recombinant Glycosylated Proteins - Erythropoietin, Monoclonal Antibodies, Follitropin) & By Application (Oncology, Blood Disorders, Growth Hormone Deficiency, Chronic & Autoimmune Disorders) And Segment Forecasts To 2024

Grand View Researchが出版した調査資料(GVIEW708055)・商品コード:GVIEW708055
・発行会社(調査会社):Grand View Research
・発行日:2016年6月
・ページ数:92
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥559,350見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥898,350見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,124,350見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
Grand View Research(米国)が発行した本調査レポートでは、バイオ後続品の世界市場について調査・分析し、バイオ後続品の世界市場動向、バイオ後続品の世界市場規模、市場予測、セグメント別バイオ後続品市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The biosimilars market is expected to reach USD 41.7 billion by 2024, according to a new report by Grand View Research, Inc. The global biosimilars market is anticipated to witness a marked growth during the period of 2016 to 2024. The most significant factor leading to the growth of this industry is the fact that major biological drugs are nearing the patent cliff. Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to cut down healthcare costs across the medical systems in the world, and the favorable clinical outcomes demonstrated through clinical trials for the biosimilar drugs is expected to boost the industry.
For the purpose of this study, the major countries considered are the U.S., Canada, the UK, Germany, India, China, Brazil, and Russia. It was estimated that in 2015, Europe accounted for the largest market share of the global biosimilars market, followed by Asia Pacific.

The industry is segmented on the basis of type of products and applications. With regard to the product type, the recombinant non-glycosylated segment is projected to flourish rapidly during the study period. On the other hand, the recombinant glycosylated proteins segment is estimated to grow at a significant CAGR during the period 2015 to 2024 due to the increasing, wide spread incidence of cancer cases (24 million by 2035), which is identified as the crucial factor driving the growth of this sector.

Further key findings from the study suggest:

North America is anticipated to be the fastest growing market during the forecast period. The biosimilars market has gained significant momentum in the U.S., presenting new opportunities for R&D and the manufacturing sector of biosimilars.

The European market is the most advanced one as it has been the first to formulate a regulatory pathway and adopt the use of biosimilars for more than 8 years now. Germany accounts for the maximum share in the biosimilars industry, followed by the rest of the European countries (UK, France, Spain, and Italy).

The Asia Pacific market is expected to witness a lucrative growth during the period 2015 to 2024. India and China are the key countries identified that are expected to lead the industry growth in the study period.

The market for oncology is estimated to soar at a rapid pace in accordance with the increasing incidence of cancer cases in the world. Additionally, the demand for cost-effective cancer treatments is expected to further fuel the industry growth.

The biosimilars market comprises several local as well as global players. Some major players of this market include Amgen, Inc., Beacon Ltd., Tea Pharmaceutical Industries Ltd., Merck & Co., Milan, Inc., Dr. Reddy’s Laboratories, Inc., Sandoz, Inc., and Celltrion Healthcare Co., Ltd.

Grand View Research has segmented the global biosimilars market on the basis of end-user, application, and region:

Biosimilars Market, by Product (Revenue, USD Million, 2013 – 2024)

Recombinant Non-Glycosylated Proteins

Insulin

Human Growth Hormones

Granulocyte Colony-stimulating Factor (G-CSF)

Interferons

Recombinant Glycosylated Proteins

Erythropoietin

Monoclonal Antibodies

Follitropin

Biosimilars Market, by Application (Revenue, USD Million, 2013 – 2024)

Oncology

Blood Disorders

Growth Hormone Deficiency

Chronic and Autoimmune Disorders

Others

Biosimilars Market, by Region (Revenue, USD Million, 2013 – 2024)

North America

U.S.

Canada

Europe

UK

Germany

Asia Pacific

China

India

Rest of the World

Brazil

Russia

【レポートの目次】

Table of Content

Chapter 1. Methodology and Scope
1.1. Research methodology
1.2. Research scope & assumption
1.3. List of data sources
Chapter 2. Executive Summary
2.1. Biosimilars Market – Industry Summary and Key Buying Criteria, 2013 – 2024
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market segmentation& scopes
4.2. Biosimilars: Market dynamics
4.2.1. Market driver analysis
4.2.1.1. Increasing emphasis on cutting down healthcare expenditures
4.2.1.2. Cost effectiveness of biosimilar drugs
4.2.1.3. Positive outcome in the ongoing clinical trials
4.2.1.4. Increasing R&D investments
4.2.1.5. Patent expiration of biologics to boost the biosimilars market
4.2.2. Market restraint analysis
4.2.2.1. High manufacturing complexities and costs
4.2.2.2. Presence of non-original biologics and biobetters
4.3. Penetration & growth prospect mapping
4.4. Biosimilars – SWOT Analysis, By Factor (political & legal, economic and technological)
4.5. Industry Analysis – Porter’s
Chapter 5. Biosimilars Market: Product Estimates & Trend Analysis
5.1. Biosimilars market: Product movement analysis
5.2. Recombinant Non-Glycosylated Proteins
5.2.1. Recombinant Non-Glycosylated Proteins Market Estimates and Forecast, 2013 to 2024 (USD Million)
5.2.1.1. Insulin
5.2.1.1.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
5.2.1.2. Human Growth Hormones
5.2.1.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
5.2.1.3. Granulocyte Colony-stimulating Factor (G-CSF)
5.2.1.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
5.2.1.4. Interferons
5.2.1.4.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
5.3. Recombinant Glycosylated Proteins
5.3.1. Recombinant Glycosylated Proteins, Market Estimates and Forecast, 2013 to 2024 (USD Million)
5.3.1.1. Erythropoietin
5.3.1.1.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
5.3.1.2. Monoclonal Antibodies
5.3.1.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
5.3.1.3. Follitropin
5.3.1.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
Chapter 6. Biosimilars Market: Application Estimates & Trend Analysis
6.1. Biosimilars market: Application movement analysis
6.2. Oncology
6.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
6.3. Blood Disorders
6.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
6.4. Growth Hormone Deficiency
6.4.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
6.5. Chronic And Autoimmune Disorders
6.5.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
6.6. Others
6.6.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
Chapter 7. Biosimilars: Regional Estimates & Trend Analysis, by Product & Application
7.1. Biosimilars Market Share (%) Analysis, by Region, 2016&2024
7.2. North America
7.2.1. U.S.
7.2.1.1. U.S. biosimilars market, by product, 2013 – 2024 (USD Million)
7.2.1.2. U.S. biosimilars market, by application, 2013 – 2024 (USD Million)
7.2.2. Canada
7.2.2.1. Canada biosimilars market, by product, 2013 – 2024 (USD Million)
7.2.2.2. Canada biosimilars market, by application, 2013 – 2024 (USD Million)
7.3. Europe
7.3.1. Germany
7.3.1.1. Germany biosimilars market, by product, 2013 – 2024 (USD Million)
7.3.1.2. Germany biosimilars market, by application, 2013 – 2024 (USD Million)
7.3.2. UK
7.3.2.1. UK biosimilars market, by product, 2013 – 2024 (USD Million)
7.3.2.2. UK biosimilars market, by application, 2013 – 2024 (USD Million)
7.4. Asia Pacific
7.4.1. China
7.4.1.1. China biosimilars market, by product, 2013 – 2024 (USD Million)
7.4.1.2. China biosimilars market, by application, 2013 – 2024 (USD Million)
7.4.2. India
7.4.2.1. India biosimilars market, by product, 2013 – 2024 (USD Million)
7.4.2.2. India biosimilars market, by application, 2013 – 2024 (USD Million)
7.5. Rest of the World
7.5.1. Brazil
7.5.1.1. Brazil biosimilars market, by product, 2013 – 2024 (USD Million)
7.5.1.2. Brazil biosimilars market, by application, 2013 – 2024 (USD Million)
7.5.2. Russia
7.5.2.1. Russia biosimilars market, by product, 2013 – 2024 (USD Million)
7.5.2.2. Russia biosimilars market, by application, 2013 – 2024 (USD Million)
Chapter 8. Competitive Landscape
8.1. Strategy framework
8.2. Market participation categorization
8.3. Company Profiles
8.3.1. Amgen, Inc.
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Biocon Ltd.
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Teva Pharmaceutical Industries Ltd.
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Merck & Co.
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Hospira, Inc.
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Mylan Pharmaceuticals, Inc.
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Dr. Reddy’s Laboratories, Inc.
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Sandoz, Inc.
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Celltrion Healthcare Co. Ltd.
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. AbbVie, Inc.
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives

List of Tables

1. Biosimilars - industry snapshot & key buying criteria, 2013 - 2024
2. Biosimilars market revenue, by product, 2013 - 2024 (USD Million)
3. Biosimilars market revenue, by application, 2013 - 2024 (USD Million)
4. Biosimilars market, by region, 2013 - 2024 (USD Million)
5. Biosimilars - key market driver analysis
6. Biosimilars - key market restraint analysis
7. North America biosimilars market revenue, by product,2013 - 2024 (USD Million)
8. North America biosimilars market revenue, by application,2013 - 2024 (USD Million)
9. U.S. biosimilars market revenue, by product,2013 - 2024 (USD Million)
10. U.S. biosimilars market revenue, by application,2013 - 2024 (USD Million)
11. Canada biosimilars market revenue, by product,2013 - 2024 (USD Million)
12. Canada biosimilars market revenue, by application,2013 - 2024 (USD Million)
13. Europe biosimilars market revenue, by product,2013 - 2024 (USD Million)
14. Europe biosimilars market revenue, by application,2013 - 2024 (USD Million)
15. Germany biosimilars market revenue, by product,2013 - 2024 (USD Million)
16. Germany biosimilars market revenue, by application,2013 - 2024 (USD Million)
17. UK biosimilars market revenue, by product, 2013 - 2024 (USD Million)
18. UK biosimilars market revenue, by application, 2013 - 2024 (USD Million)
19. AsiaPacific biosimilars market revenue, by product,2013 - 2024 (USD Million)
20. Asia Pacific biosimilars market revenue, by application, 2013 - 2024 (USD Million)
21. China biosimilars market revenue, by product, 2013 - 2024 (USD Million)
22. China biosimilars market revenue, by application, 2013 - 2024 (USD Million)
23. India biosimilars market revenue, by product, 2013 - 2024 (USD Million)
24. India biosimilars market revenue, by application, 2013 - 2024 (USD Million)
25. Rest of the world biosimilars market revenue, by product, 2013 - 2024 (USD Million)
26. Rest of the world biosimilars market revenue, by application, 2013 - 2024 (USD Million)
27. Brazil biosimilars market revenue, by product,2013 - 2024 (USD Million)
28. Brazil biosimilars market revenue, by application,2013 - 2024 (USD Million)
29. Russia biosimilars market revenue, by product,2013 - 2024 (USD Million)
30. Russia biosimilars market revenue, by application , 2013 - 2024 (USD Million)

List of Figures

1. Biosimilars: Market segmentation
2. Biosimilars, 2013 - 2024 (USD Million)
3. Biosimilars market: Industry trend analysis
4. Biosimilars market: PESTEL analysis
5. Global Biosimilars market: Porter’s analysis
6. Biosimilars company market share, 2015
7. Key Opportunities Prioritized
8. Biosimilars market revenue share by product, 2016 & 2024
9. Biosimilars market by product market revenue, 2013 to 2024 (USD Million)
10. Biosimilars market by application market revenue, 2013 to 2024 (USD Million)
11. Biosimilars market share, by region, 2016 & 2024

【レポートのキーワード】

バイオ後続品、バイオシミラー、医薬品、インスリン、G-CSF、インターフェロン

★調査レポート[バイオ後続品の世界市場分析] (コード:GVIEW708055)販売に関する免責事項を必ずご確認ください。
★調査レポート[バイオ後続品の世界市場分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆